Reirradiation as part of a salvage treatment approach for progressive non-pontine pediatric high-grade gliomas: preliminary experiences from the German HIT-HGG study group

Table 1 Patients characteristics I, first-line treatment and time to first progression

Patient	Age at initial Dx (years)/gender	Tumor location	Pathology	First-line treatment	RT 1 Gy/fractions/concurrent chemotherapy	Maintenance chemotherapy	Time from initial Dx to first relapse (months)
1	11/M	temporo-parietal	AA	pSx → RCT → mCT	54.0/27/ PEV/VCR/PEIV	TMZ	9.5
2	15/M	central	AA/GBM*	pSx → MTX → RCT → second surgery → mCT	59.4/33/ PEV/VCR/PEIV	CCNU/VCR (VBL)	17.4
3	10/F	frontal	AOD	pSx → RCT → mCT	59.4/33/ PEV/VCR/PEIV	CCNU/VCR/prednisolone	9.4
4	13/F	parietal + insular	GBM	pSx → RCT → mCT	60/30/TMZ	TMZ	5.0
5	13/M	frontal	GBM	pSx → RCT → mCT	59.4/33/ TMZ	TMZ	49.9
6	14/M	hemispheric	AA	Bx →CT (carboplatin, etoposide, VCR) → RCT → mCT	54/30/ PEV/VCR/PEIV	CCNU/VCR/prednisolone	12.2
7	10/M	temporal	GBM	pSx → RCT →PD → mCT	59.4/33/ TMZ	TMZ	2.5
8	16/F	thalamic	AA	pSx → RCT →mCT	59.4/33/ TMZ	TMZ	9.0

Dx: diagnosis, M: male, F: female, AA: anaplastic astrocytoma (WHO grade III), AOD: anaplastic oligodendroglioma (WHO grade III), GBM: glioblastoma multiforme (WHO grade IV), Bx: biopsy, pSx: partial surgery, RT: radiation therapy, RCT: radiochemotherapy, mCT: maintenance chemotherapy, TMZ: temozolomide, CCNU: lomustine, PEV: cisplatin, vincristine, CCNU, VCR: vincristine, VBL: vinblastine, PEIV: cisplatin, vincristine, CCNU, ifosfamide, PD: progressive disease. →: followinged by the next treatment.
*AA at initial diagnosis, GBM at first recurrence.

ISSN: 1748-717X